Although we have demonstrated that pharmacological inhibition of MST1/2 can impede ER+ breast cancer growth in vivo, the subcutaneous xenograft model employed in our study requires supraphysiological concentrations of estrogen and thus may compromise clinical relevance. Here, MST1 is linked to breast cancer.